JUNO THERAPEUTICS INC (JUNO) Fundamental Analysis & Valuation
NASDAQ:JUNO • US48205A1097
Current stock price
86.96
+0.09 (+0.1%)
Last:
This JUNO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
No Fundamental Analysis report for JUNO not available.
JUNO Fundamentals: All Metrics, Ratios and Statistics
NASDAQ:JUNO (3/5/2018, 8:38:56 PM)
86.96
+0.09 (+0.1%)
Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners70.19%
Inst Owner ChangeN/A
Ins Owners10.21%
Ins Owner Change0%
Market Cap10.10B
Revenue(TTM)111.87M
Net Income(TTM)-437.11M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0
Dividend Growth(5Y)0%
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 90.26 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 9.64 | ||
| P/tB | N/A | ||
| EV/EBITDA | -22.12 |
EPS(TTM)-4.1
EYN/A
EPS(NY)-4.83
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.96
BVpS9.02
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.46% | ||
| ROE | -41.75% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | -390.72% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.61 | ||
| Quick Ratio | 3.61 | ||
| Altman-Z | 13.9 |
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-69.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-140.65%
EPS Next Y-17.89%
EPS Next 2Y-37.78%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)40.97%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%25.09%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A
JUNO THERAPEUTICS INC / JUNO Fundamental Analysis FAQ
What is the ChartMill fundamental rating of JUNO THERAPEUTICS INC (JUNO) stock?
ChartMill assigns a fundamental rating of 3 / 10 to JUNO.
What is the valuation status for JUNO stock?
ChartMill assigns a valuation rating of 1 / 10 to JUNO THERAPEUTICS INC (JUNO). This can be considered as Overvalued.
What is the profitability of JUNO stock?
JUNO THERAPEUTICS INC (JUNO) has a profitability rating of 2 / 10.
Can you provide the expected EPS growth for JUNO stock?
The Earnings per Share (EPS) of JUNO THERAPEUTICS INC (JUNO) is expected to decline by -17.89% in the next year.